This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Vitamin D Treatment for Crohn´s Disease

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2007 by University of Aarhus.
Recruitment status was:  Active, not recruiting
Information provided by:
University of Aarhus Identifier:
First received: August 18, 2005
Last updated: April 12, 2007
Last verified: April 2007
The purpose of this study is to examine whether vitamin D treatment is effective in Crohn's disease.

Condition Intervention Phase
Crohns Disease Drug: Vitamin D Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Remission Keeping and Remission Inducing Effect by Vitamin-D in Crohns Disease, and in Vitro Vitamin-D Mediated T-Cell Immunomodulation

Resource links provided by NLM:

Further study details as provided by University of Aarhus:

Primary Outcome Measures:
  • Relapse rate within 1 year treatment; CDAI>220

Estimated Enrollment: 110
Study Start Date: September 2005
Estimated Study Completion Date: February 2008
Detailed Description:

Crohns Disease is an inflammatory disease of primarily the small intestine and colon.

In recent years scientists have hypothesized that low blood vitamin-D levels play a role in the development of autoimmune diseases, including Crohns disease. The purpose of this study is to examine whether vitamin-D is effective in keeping remission in inactive Crohns Disease (double blind placebo controlled trial). The patients who have active disease in the placebo group (reach primary endpoint), will in an open setting receive a higher single dose vitamin-D and the effect will be measured within 4 weeks.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Crohn's disease
  • Inactive Crohn's disease for at least 4 weeks
  • Crohn's Disease Activity Index (CDAI) < 150
  • C-reactive protein within normal range
  • Serum albumin within normal range

Exclusion Criteria:

  • Hypercalcemia
  • Short bowel syndrome
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00132184

Aarhus University Hospital, Department V
Aarhus, Denmark, 8000
Hospital of Horsens
Horsens, Denmark, 8700
Hospital of Randers
Randers, Denmark, 8900
Hospital of Silkeborg
Silkeborg, Denmark, 8600
Sponsors and Collaborators
University of Aarhus
Principal Investigator: Jens F. Dahlerup, MD, DrMedSc Aarhus University Hospital
  More Information Identifier: NCT00132184     History of Changes
Other Study ID Numbers: 2005-001216-50
Study First Received: August 18, 2005
Last Updated: April 12, 2007

Keywords provided by University of Aarhus:
Vitamin D
Crohns Disease

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents processed this record on August 17, 2017